AMA applauds FDA for approving naloxone product to prevent overdoses

| 2 Min Read

“The American Medical Association (AMA) applauds the Food and Drug Administration (FDA) for approving the nasal spray version of naloxone, a life-saving medication that can reverse the effects of an opioid overdose by restoring breathing and preventing death. The FDA’s swift action will widely increase accessibility to this medication that will help prevent more opioid-related overdoses and save more lives.

“The AMA has long advocated in support of a multi-pronged approach to addressing prescription drug abuse and diversion, which includes increasing access to naloxone for patients who need it.

Full press statement available when you sign in

Sign in to the AMA website to get the full version of this press statement. 

AMA membership has its advantages

  • Be a part of the nation's largest physician organization
  • Play a role in shaping the future of health care
  • Enjoy exclusive perks and savings

Not a member? Become a member now.

 

FEATURED STORIES

Fingers point to activity trackers on smartwatches

Which specialties lead the way on using wearable data for care

| 7 Min Read
Stethoscope hanging on railing inside hospital

4 top factors that drive physicians to give up clinical practice

| 5 Min Read
Senior man using a phone at a clinic

CMS ACCESS Model launches in July: What doctors should know

| 5 Min Read
Chelsea Evans, DO, featured on "Health vs. Hype" AMA podcast

4 things to know about cold plunges and contrast therapy

| 5 Min Read